Convergent Dental Announces New Agreement with Henry Schein, Making the Solea®️ Dental Laser Available to More US Dental Professionals
September 5, 2019
NEEDHAM, Mass. (September 5, 2019) – Convergent Dental, Inc., developer of Solea, the industry-leading 9.3 µm CO2 all-tissue dental laser, is excited to announce a new distribution agreement with Henry Schein Dental, the U.S. dental business of Henry Schein, Inc., the world’s largest supplier of health solutions to office-based dental and medical practitioners. The Solea laser is the first and only CO2 laser FDA-cleared to cut hard, soft, and osseous tissue across the US.
“Adding Solea to the market has had a profound effect on dentistry, and we believe our new agreement with Henry Schein will do the same,” stated Michael Cataldo, CEO of Convergent Dental. “Henry Schein is a trusted leader in dental product and technology distribution and this new agreement will help us to provide dental practices nationwide with access to our revolutionary, reliably anesthesia-free laser.”
Known for enabling practitioners to work anesthesia-, blood-, and suture-free, as well as significantly reducing anxiety from procedures, creating better experiences for patients, Solea is dentistry’s number one selling all-tissue dental laser. Although developed with advanced science, the technology is simple to learn and use. With the virtual push of a button, practitioners can guide Solea back and forth between hard, soft, and osseous tissue by adjusting the pressure on its variable speed foot pedal.
“Henry Schein customers rely on us to provide unique products and solutions that save them time and enhance their practices,” said AJ Caffentzis, President, US Dental Distribution, Henry Schein, Inc. “This distribution agreement reinforces our commitment to helping dentists achieve maximum practice efficiency, so they can focus on patient care.”
For more information about Solea, please visit convergentdental.com or call 844.GOSOLEA.
About Convergent Dental, Inc.
Convergent Dental, Inc. is a privately owned dental equipment and technology company. Solea is the only computer-aided, CO2 laser system to be cleared by the FDA for all-tissue indications. With Solea’s unique wavelength and computer controls, dentists can reliably perform procedures anesthesia-free, blood-free, suture-free, and pain-free. Reliably anesthesia-free and blood-free procedures pay huge dividends for patients in the form of a vastly improved dental experience and dentists in terms of significant practice growth. For more information, please visit www.convergentdental.com. Follow the company on Twitter, Facebook, LinkedIn and Instagram.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 19,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.
A FORTUNE 500 Company and a member of the S&P 500 and the Nasdaq 100 indexes, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries. The Company’s sales from continuing operations reached $9.4 billion in 2018, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.
Read the full press release here.